サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1534101

神経膠腫の治療の世界市場

Glioma Treatment

出版日
ページ情報
英文 250 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
神経膠腫の治療の世界市場
出版日: 2024年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 250 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経膠腫の治療の世界市場は2030年までに83億米ドルに達する見込み

2023年に49億米ドルと推定される神経膠腫の治療の世界市場は、分析期間2023-2030年にCAGR 8.0％で成長し、2030年には83億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである手術は、CAGR 6.8%を記録し、分析期間終了時には29億米ドルに達すると予測されます。化学療法分野の成長率は、分析期間中CAGR 7.0％と推定されます。

米国市場は13億米ドルと推定、中国はCAGR 7.7％で成長予測

米国の神経膠腫の治療市場は2023年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに13億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは7.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.1%と6.9%と予測されています。欧州では、ドイツがCAGR約6.5%で成長すると予測されています。

世界の神経膠腫の治療市場- 主要動向と促進要因のまとめ

神経膠腫は、中枢神経系のニューロンを支え保護するグリア細胞に由来する多様な脳腫瘍群です。神経膠腫の治療は、腫瘍の悪性度、部位、遺伝的特徴によって大きく異なります。膠芽腫などの悪性度の高い神経膠腫は特に侵攻性が高く、治療が困難であるため、通常、手術、放射線療法、化学療法を含む多剤併用療法が必要となります。経口化学療法薬であるテモゾロミドは、血液脳関門を通過する能力があり、患者の転帰を改善することから、放射線療法との併用が一般的です。分子プロファイリングにおける最近の進歩は、標的療法や免疫療法が特定の遺伝子変異を有する患者に新たな希望を提供するなど、より個別化された治療戦略につながっています。

神経膠腫の革新的治療は、バイオテクノロジーの飛躍的進歩と腫瘍生物学のより深い理解によって推進されています。個人の遺伝的体質に基づいて治療を調整する精密医療のアプローチは、有効性を高め副作用を最小化するために採用されるようになってきています。例えば、IDH1/2阻害剤やEGFR阻害剤のような特定の変異を標的とする治療法は、臨床試験で活発に研究されています。さらに、チェックポイント阻害剤やCAR-T細胞療法を含む免疫療法は、神経膠腫細胞と闘うために身体の免疫系を利用することに有望です。対流促進デリバリーやナノ粒子ベースのキャリアなどのドラッグデリバリーシステムの進歩により、化学療法剤の標的送達も改善されつつあり、これにより腫瘍部位での濃度を高めつつ、全身毒性を軽減することができます。

神経膠腫の治療市場の成長は、いくつかの要因によって牽引されています。なかでも重要なのは、神経膠腫の発生率の増加と、効果的な治療法に対するアンメット・メディカル・ニーズの高さです。分子診断の技術的進歩は、対処可能な遺伝子変異の同定を可能にし、標的療法の採用を促進しています。免疫療法の分野の拡大と他のがん種での成功が、神経膠腫に特異的な免疫ベースの治療への投資に拍車をかけています。さらに、新しいドラッグデリバリー機構の開発により、既存の治療の精度と有効性が向上し、治療の展望が広がっています。脳腫瘍研究に対する政府および民間部門の資金援助は、希少疾病用医薬品の指定などの規制上の優遇措置とともに、市場の成長をさらに後押ししています。さらに、神経膠腫の症状に対する認識の高まりと画像診断技術の進歩は、早期診断と早期介入に寄与し、治療成績を向上させ、先進治療への需要を促進しています。これらの要因が相まって、神経膠腫治療市場はダイナミックかつ急速に発展しています。

調査対象企業の例（全86件）

  • Amgen Inc.
  • Amneal Pharmaceuticals, LLC
  • Ariceum Therapeutics GmbH
  • Azurity Pharmaceuticals, Inc.（Gliade）
  • Bristol-Myers Squibb Company
  • CNS Therapeutics, Inc.
  • Denovo Biopharma LLC
  • Elekta
  • F. Hoffmann-La Roche Ltd.,
  • ITM Isotope Technologies Munich SE
  • Karyopharm Therapeutics, Inc.
  • Lantern Pharma Inc.
  • Novartis AG
  • Novocure
  • VBI Vaccines Inc.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP26847

Global Glioma Treatment Market to Reach US$8.3 Billion by 2030

The global market for Glioma Treatment estimated at US$4.9 Billion in the year 2023, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 8.0% over the analysis period 2023-2030. Surgery, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 7.7% CAGR

The Glioma Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Glioma Treatment Market - Key Trends and Drivers Summarized

Gliomas are a diverse group of brain tumors originating from glial cells, which support and protect neurons in the central nervous system. Treatment of gliomas varies significantly based on the tumor's grade, location, and genetic characteristics. High-grade gliomas, such as glioblastomas, are particularly aggressive and challenging to treat, necessitating a multimodal approach that typically includes surgery, radiation therapy, and chemotherapy. Temozolomide, an oral chemotherapy drug, is commonly used in combination with radiotherapy due to its ability to penetrate the blood-brain barrier and improve patient outcomes. Recent advancements in molecular profiling have led to more personalized treatment strategies, with targeted therapies and immunotherapies offering new hope for patients with specific genetic mutations.

Innovative treatments for glioma are being driven by breakthroughs in biotechnology and a deeper understanding of tumor biology. Precision medicine approaches, which tailor treatments based on an individual’s genetic makeup, are increasingly employed to enhance efficacy and minimize side effects. For instance, therapies targeting specific mutations such as IDH1/2 inhibitors and EGFR inhibitors are under active investigation in clinical trials. Additionally, immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, has shown promise in harnessing the body’s immune system to combat glioma cells. Advances in drug delivery systems, such as convection-enhanced delivery and nanoparticle-based carriers, are also improving the targeted delivery of chemotherapeutic agents, thereby increasing their concentration at the tumor site while reducing systemic toxicity.

The growth in the glioma treatment market is driven by several factors. Key among these is the increasing incidence of gliomas and the significant unmet medical need for effective therapies. Technological advancements in molecular diagnostics have enabled the identification of actionable genetic mutations, driving the adoption of targeted therapies. The expanding field of immunotherapy and its success in other cancer types have spurred investment in glioma-specific immune-based treatments. Additionally, the development of novel drug delivery mechanisms has expanded the therapeutic landscape by improving the precision and efficacy of existing treatments. Government and private sector funding for brain cancer research, along with regulatory incentives such as orphan drug designations, further propel market growth. Moreover, growing awareness of glioma symptoms and advancements in imaging technologies contribute to earlier diagnosis and intervention, improving treatment outcomes and driving demand for advanced therapies. Collectively, these factors are fostering a dynamic and rapidly evolving market for glioma treatments.

Select Competitors (Total 86 Featured) -

  • Amgen Inc.
  • Amneal Pharmaceuticals, LLC
  • Ariceum Therapeutics GmbH
  • Azurity Pharmaceuticals, Inc. (Gliade)
  • Bristol-Myers Squibb Company
  • CNS Therapeutics, Inc.
  • Denovo Biopharma LLC
  • Elekta
  • F. Hoffmann-La Roche Ltd.,
  • ITM Isotope Technologies Munich SE
  • Karyopharm Therapeutics, Inc.
  • Lantern Pharma Inc.
  • Novartis AG
  • Novocure
  • VBI Vaccines Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Glioma Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Gliomas Spurs Demand for Effective Therapies
    • Technological Advancements in Molecular Diagnostics Propel Growth
    • Precision Medicine Approaches Expand Addressable Market Opportunity
    • Development of Targeted Therapies Strengthens Business Case for Personalized Treatment
    • Increasing Adoption of Immunotherapy Drives Market Expansion
    • Novel Drug Delivery Systems Generate New Market Opportunities
    • Advances in Imaging Technologies Drive Early Diagnosis and Intervention
    • Growing Awareness of Glioma Symptoms Spurs Demand for Advanced Therapies
    • Here's How Molecular Profiling Enhances Treatment Personalization
    • Expanding Field of Genetic Research Generates Opportunities for Novel Treatments
    • Increasing Use of AI and Machine Learning in Drug Discovery Spurs Growth
    • Advances in Biomarker Identification Generate New Avenues for Targeted Therapy
    • Integration of Telemedicine and Remote Monitoring Technologies Expands Access to Care
    • Rising Investment in Oncology Propels Market Expansion for Glioma Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Glioma Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Glioma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Glioma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Glioma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • CHINA
    • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Glioma Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Glioma Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Glioma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 56: Rest of World Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of World Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of World 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

IV. COMPETITION